News

Topline data from this dose regimen trial is expected in the first half of 2020. “We are extremely grateful to the patients who volunteer to participate in our

Keytruda is Merck’s anti-PD-1 therapy, while Lenvima is the orally available kinase inhibitor discovered by Eisai. Keytruda plus Lenvima has been approved for the treatment of patients with

This study aims to confirm the predicted relative exposure and dose proportionality of PXL065. PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, targets mitochondrial pyruvate carrier (MPC) inhibition. PXL065 is

The primary endpoint is the change from baseline in the 6-minute walk test (6-MWT) at 12 months. Secondary endpoints will evaluate the efficacy of patisiran on quality of

The fast track designation is for the use of Farxiga in reducing the chances of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart

The Allergenic Products Advisory Committee (APAC) voted seven to two that the efficacy data and eight to one that the safety data, along with other safeguards, are enough

The platform, which went live at Bayer earlier this year, brings internal and external clinical data together with Oracle cloud-based technologies into a single data management and warehousing

Alder BioPharmaceuticals is involved in the discovery, development and commercialisation of novel therapeutic antibodies. As per terms of the deal, Lundbeck will begin a tender offer for all

The data demonstrate that, in two Phase I single-dose clinical studies in healthy volunteers, ARO-APOC3 reduced plasma Apolipoprotein C-III (apoC-III) and ARO-ANG3 reduced plasma angiopoietin like protein 3